The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?
Launched by UNIVERSITY OF SYDNEY · Nov 13, 2015
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
Most preterm babies have the umbilical cord clamped within 10 seconds of birth. Placental transfusion is a simple way of giving the baby extra blood at birth by delaying the clamping of the umbilical cord by 60 seconds or more. There is promising evidence from randomised trials that placental transfusion in babies less than 37 weeks of pregnancy may improve their blood pressure, reduce the number of blood transfusions needed and decrease bleeding into the brain, bowel disease and infection. However, we not know if babies born before 30 weeks of pregnancy benefit or if placental transfusion ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women who have a reasonable chance of delivering less than 30 weeks of gestation. Informed consent has been received from the parent or guardian.
- Exclusion Criteria:
- • No indication or contraindication to placental transfusion, in the view of mother or baby.
About University Of Sydney
The University of Sydney is a leading research institution in Australia, renowned for its commitment to advancing medical science and improving healthcare outcomes through innovative clinical trials. With a robust infrastructure and a multidisciplinary team of experts, the university fosters a collaborative environment that integrates cutting-edge research with clinical practice. The institution emphasizes ethical standards, patient safety, and scientific rigor in its trials, aiming to translate findings into real-world applications that benefit diverse populations. Through its dedication to excellence and impact, the University of Sydney continues to contribute significantly to the fields of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Craigavon, Northern Ireland, United Kingdom
Christchurch, , New Zealand
Sydney, New South Wales, Australia
Perth, Western Australia, Australia
Sydney, New South Wales, Australia
Canberra, Australian Capital Territory, Australia
Adelaide, South Australia, Australia
Wellington, , New Zealand
Auckland, , New Zealand
Hamilton, , New Zealand
Townsville, Queensland, Australia
Dunedin, , New Zealand
Newcastle, New South Wales, Australia
Sydney, New South Wales, Australia
Burlington, Vermont, United States
Karachi, , Pakistan
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Brisbane, Queensland, Australia
Brisbane, Queensland, Australia
Melbourne, Victoria, Australia
Melbourne, Victoria, Australia
Halifax, Nova Scotia, Canada
Clamart, , France
Belfast, Northern Ireland, United Kingdom
Patients applied
Trial Officials
William T Mordi, MD
Principal Investigator
University of Sydney
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials